HURA7:45 AMTuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancerstuhurabio.com
HURA5:00 PMTuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Updatetuhurabio.com
HURA7:30 AMTuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conferencetuhurabio.com
HURA7:30 AMTuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028tuhurabio.com